| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4f261d1abe09c80caff60d34649a4c19 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-496
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7072
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-365 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7072
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-496
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-365 |
| filingDate |
2021-03-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_65bfd9f661c465d00e8bfc907fb78ec8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e88475431844b363d91f34325dfb2d67
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_68f2b6bec318830107621645eb48ff9b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d937242e799ca0cdfacb17ac1d6cd23a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c6e071da838ba453b0a641e312e64608
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_20dfa70e974e57eb449d82298dd19b9d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_83b9be7f16dc6d42587a26ea7c04cc42
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_91422b826e7c982505dc90604d4d875d |
| publicationDate |
2021-06-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-112891354-A |
| titleOfInvention |
Application of MDM2 Inhibitor Nutlin-3a in the Preparation of Drugs for Activating Endoplasmic Reticulum Stress-Induced Cancer Cell Apoptosis |
| abstract |
The invention discloses the application of an MDM2 inhibitor Nutlin-3a in the preparation of a drug for activating apoptosis of cancer cells induced by endoplasmic reticulum stress. Experiments have confirmed that the MDM2 inhibitor Nutlin-3a can induce the occurrence of endoplasmic reticulum stress by increasing the concentration of intracytoplasmic calcium ions, thereby activating the death receptor pathway to induce apoptosis in colon cancer cells. The invention also discloses an anti-tumor pharmaceutical composition of an MDM2 inhibitor Nutlin-3a and an endoplasmic reticulum stress activator. Both in vitro and in vivo experiments have confirmed that the pharmaceutical composition has significant synergistic effect and good efficacy in the treatment of colon cancer. antitumor effect. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113913519-A |
| priorityDate |
2021-03-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |